Heparin after acute myocardial infarction

Cardiovascular Drugs and Therapy

Volumn 11, Issue 2, 1997, Pages 101-109

  Commerford, Patrick Joseph ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Acute myocardial infarction; Embolism haemorrhage; Heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN;

ACUTE HEART INFARCTION; ARTICLE; BRAIN EMBOLISM; HEART VENTRICLE THROMBOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

ACUTE DISEASE; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME;

EID: 0030905459     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007724628936     Document Type: Article

References (43)

1. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br Heart J 1985;53:363-373.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50:310-318.
3. Cerebral Embolism Task Force. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. Arch Neurol 1989;46:727-743.
4. Guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Sub-Committee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 1990;16:249-292.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349-360.
6. O'Donnell CJ, Ridker PM, Hebert PR, Hennekens CH. Antithrombotic therapy for acute myocardial infarction. J Am Coll Cardiol 1995;25(Suppl):23S-29S.
7. Ridker PM, Hebert PR, Fuster V, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993; 341:1574-1577.
8. McMurray J, Rankin A. Cardiology-I. Treatment of myocardial infarction, unstable angina and angina pectoris. Br Med J 1994;309:1343-1350.
9. Rogers WJ, Bowlby LJ, Chandra NC, et al. for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-2114.
10. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994;343:311-322.
11. Verheught FWA, Meijer A, Lagrand WK, van Eenige MJ. Reocclusion: The flip side of coronary thrombolysis. J Am Coll Cardiol 1996;27:766-773.
12. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791.
13. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-150.
14. Aronson DL, Chang P, Kessler CM. Platelet-dependent thrombi generation after in vitro fibrinolytic treatment. Circulation 1992;85:1706-1712.
15. Gash AK, Spann JF, Sherky S, et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986;57:175-177.
16. Inoue K, Ochiai H, Kuwaki K. The mechanism of reocclusion after successful coronary thrombolysis as validated by percutaneous angioscopy (abstract). J Am Coll Cardiol 1994; 23:13A.
17. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomised trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996;77:551-556.
18. Hsia J, Kleiman NS, Aguirre FV, Chaitman BR, Roberts R, Ross AM. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency. J Am Coll Cardiol 1992;20:31-35.
19. Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 1992;20:513-519.
20. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
21. Granger CB, Hirsh J, Califf RM, et al. for the GUSTO-I Investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Results from the GUSTO-I Trial. Circulation 1996;93:870-878.
22. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145.
23. Di Tano G, Mazzu A. Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction. Br Heart J 1995;74:131-133.
24. Antman EM for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-921.
25. Gruppo Italiano per lo Studio della Sopravivenza Nell' Infarto Miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
26. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomized comparison of streptokinase versus tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
27. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
28. The Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
29. Antman EM, for the TIMI 9a Investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9a trial. Circulation 1994;90:1624-1630.
30. MacMahon S, Collins R, Knight C, Yusuf S, Peto R. Reduction in major morbidity and mortality by heparin in acute myocardial infarction (abstract). Circulation 1988;78(Suppl II):II93.
31. Assessment of short-term anticoagulant administration after cardiac infarction. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. Br Med J 1981;1:335-342.
32. Anticoagulants in acute myocardial infarction. Results of a co-operative clinical trial. JAMA 1973;225:724-30.
33. Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patients age, sex and severity of infarction. JAMA 1972;222:541-548.
34. McGovern PG, Pankow JS, Shahar E, et al. for the Minnesota Heart Survey Investigators. Recent trends in acute coronary heart disease. Mortality, morbidity, medical care and risk factors. N Engl J Med 1996;334:884-890.
35. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-766.
36. Fuster V, Halperin JL. Left ventricular thrombi and cerebral embolism. N Engl J Med 1989;320:392-393.
37. Vaitkus PT, Berlin JA, Schwartz JS, Barnathan ES. Stroke complicating acute myocardial infarction. A meta-analysis of risk modification by anticoagulation and thrombolytic therapy. Arch Intern Med 1992;152:2020-2024.
38. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989;320:352-357.
39. Bodenheimer MM, Sauer D, Shareef B, Brown MW, Fleiss JL, Moss AJ. Relation between myocardial infarct location and stroke. J Am Coll Cardiol 1994;4:61-66.
40. Nihoyannopoulos P, Smith GC, Maseri A, Foale RA. The natural history of left ventricular thrombus in myocardial infarction: A rationale in support of masterly inactivity. J Am Coll Cardiol 1989;14:903-911.
41. Halperin JL, Fuster V. Left ventricular thrombus and stroke after myocardial infarction: Toward prevention or perplexity? J Am Coll Cardiol 1989;14:912-914.
42. Loscalzo J. Thrombin inhibitors in fibrinolysis. A Hobson's choice of alternatives. Circulation 1996;94:863-865.
43. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br Med J 1996;313:652-659.